| Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma) (NCT01669668) | Washington University School of Medicine | 2014-12-01 |
| Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Patients (NCT02580929) | Peking Union Medical College | 2014-10-01 |
| Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma (NCT02293850) | Oncolys BioPharma Inc | 2014-10-01 |
| SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE (NCT02221778) | University of Sao Paulo | 2014-08-01 |
| Hepatocellular Carcinoma and Rheumatoid Arthritis (NCT02880306) | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 2014-07-01 |
| Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma (NCT06571396) | Qilu Hospital of Shandong University | 2014-04-01 |
| Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity (NCT02148562) | Universitaire Ziekenhuizen KU Leuven | 2014-04-01 |
| A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (NCT02069041) | Eli Lilly and Company | 2014-04-01 |
| Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) (NCT02329860) | Jiangsu HengRui Medicine Co., Ltd. | 2014-03-26 |
| Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer (NCT02081755) | Baylor Research Institute | 2014-03-01 |
| Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma (NCT01988493) | Merck KGaA, Darmstadt, Germany | 2014-01-06 |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC (NCT02018757) | First Hospital of China Medical University | 2014-01-01 |
| Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib (NCT01933945) | Bayer | 2013-10-28 |
| A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer (NCT01911273) | Pfizer | 2013-10-01 |
| Circulating Tumor Cells for Hepatocellular Carcinoma (NCT01930383) | National Taiwan University Hospital | 2013-10-01 |
| Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) (NCT01915589) | Bayer | 2013-09-16 |
| Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma (NCT02403544) | Chinese Academy of Medical Sciences | 2013-09-01 |
| Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis (NCT01911000) | Samsung Medical Center | 2013-09-01 |
| A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma (NCT01897038) | Hoffmann-La Roche | 2013-09-01 |
| Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety (NCT01908322) | Bayer | 2013-08-01 |
| Sorafenib for Residue Disease After Resection With Curative Intent (NCT01751763) | Bayer | 2013-07-09 |
| A Study of rSIFN-co in Subjects With Advanced Solid Tumors (NCT02387307) | Sichuan Huiyang Life Science and Technology Corporation | 2013-07-01 |
| Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma (NCT01861912) | Guangdong Provincial People's Hospital | 2013-06-01 |
| Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China (NCT01839630) | Bayer | 2013-05-30 |
| Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (NCT01774344) | Bayer | 2013-05-14 |
| Risk of Hepatocellular Carcinoma in Patient With Liver Cirrhosis (NCT03083002) | University of Modena and Reggio Emilia | 2013-05-01 |
| Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests (NCT01790633) | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | 2013-02-01 |
| Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase (NCT01715532) | Fudan University | 2012-07-01 |
| TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma (NCT01605734) | Shandong Cancer Hospital and Institute | 2012-07-01 |
| Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization (NCT02848638) | University of Washington | 2012-07-01 |
| Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (NCT01655693) | Valerio Therapeutics | 2012-06-01 |
| Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma (NCT01594125) | Boehringer Ingelheim | 2012-05-01 |
| A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (NCT01507168) | Hoffmann-La Roche | 2012-02-02 |
| Application of HBV Rapid Tests as a Tool for Wide-Use Screening (NCT01767597) | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | 2012-02-01 |
| Advanced Image Guidance Utilized in Liver Surgery (NCT01666145) | Wake Forest University Health Sciences | 2012-02-01 |
| A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. (NCT01441388) | Pfizer | 2011-12-01 |
| A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma (NCT01425996) | Taiwan Liposome Company | 2011-10-27 |
| HCC Response Assessment by MRI After SBRT (NCT03088423) | Institut de Cancérologie de Lorraine | 2011-10-01 |
| 3T MRI to Predict TACE Response of HCC (NCT02070822) | National Taiwan University Hospital | 2011-08-01 |
| TRC105 for Liver Cancer That Has Not Responded to Sorafenib (NCT01375569) | National Cancer Institute (NCI) | 2011-06-22 |
| Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease (NCT01355107) | University Hospital Freiburg | 2011-04-01 |
| A Study of LY2157299 in Participants With Hepatocellular Carcinoma (NCT01246986) | Eli Lilly and Company | 2011-03-30 |
| A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma (NCT01308723) | Hoffmann-La Roche | 2011-03-01 |
| Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (NCT01393093) | Tianjin Medical University Cancer Institute and Hospital | 2011-03-01 |
| Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG) (NCT01393197) | Tianjin Medical University Cancer Institute and Hospital | 2011-03-01 |
| Sorafenib and TRC105 in Hepatocellular Cancer (NCT01306058) | National Cancer Institute (NCI) | 2011-02-11 |
| Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (NCT01258608) | Human Genome Sciences Inc., a GSK Company | 2011-02-08 |
| Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma (NCT01327521) | Albert Koong | 2011-02-01 |
| Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. (NCT01204177) | Bayer | 2010-12-01 |
| GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start (NCT01191385) | Bayer | 2010-11-01 |
| Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC (NCT01214343) | Ministry of Health, Labour and Welfare, Japan | 2010-10-01 |
| Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (NCT01217034) | Kindai University | 2010-10-01 |
| Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria (NCT01141478) | Loma Linda University | 2010-09-08 |
| Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT) (NCT01337492) | Case Comprehensive Cancer Center | 2010-09-01 |
| The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer (NCT01310062) | Ministry of Health, Malaysia | 2010-08-01 |
| Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants (NCT02366286) | Mayo Clinic | 2010-07-27 |
| Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment (NCT01108705) | Bristol-Myers Squibb | 2010-05-01 |
| Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC) (NCT01078415) | Angiodynamics, Inc. | 2010-02-01 |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) (NCT01009593) | Abbott | 2010-01-01 |
| Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis (NCT01201655) | Xijing Hospital | 2010-01-01 |
| Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma (NCT01668134) | Washington University School of Medicine | 2009-12-16 |
| Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas (NCT01040559) | Centre Hospitalier Universitaire Dijon | 2009-12-01 |
| Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (NCT01004003) | Boehringer Ingelheim | 2009-10-22 |
| Regulatory Post Marketing Surveillance Study on Nexavar® (NCT01012011) | Bayer | 2009-09-01 |
| Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma (NCT01020812) | Stanford University | 2009-09-01 |
| Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma (NCT01003015) | Bayer | 2009-09-01 |
| Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer (NCT00920192) | GlaxoSmithKline | 2009-08-12 |
| A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area (NCT00913757) | National Cancer Institute (NCI) | 2009-07-01 |
| Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC) (NCT00919009) | National Cancer Center, Korea | 2009-06-01 |
| A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma (NCT01171651) | Jennerex Biotherapeutics | 2009-05-26 |
| Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (NCT00901901) | Bayer | 2009-05-21 |
| Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan (NCT01411436) | Bayer | 2009-05-01 |
| Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance (NCT00926536) | Stanford University | 2009-04-01 |
| Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (NCT00843934) | Nihon University | 2009-03-01 |
| A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). (NCT00855218) | Bayer | 2009-03-01 |
| Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma (NCT00827723) | University of Lausanne Hospitals | 2009-02-01 |
| Proteomic Analysis of Human Hepatocellular Carcinoma (NCT01177631) | Far Eastern Memorial Hospital | 2009-02-01 |
| Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma (NCT00857805) | Loma Linda University | 2009-01-07 |
| Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (NCT00812175) | Bayer | 2009-01-01 |
| Radiofrequency Versus Laser Ablation for Hepatocellular Carcinoma (NCT01096914) | Cardarelli Hospital | 2009-01-01 |
| Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas (NCT04172194) | Centre Hospitalier Universitaire de Nice | 2009-01-01 |
| CIK Treatment for HCC Patient Underwent Radical Resection (NCT01749865) | Sun Yat-sen University | 2008-10-01 |
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) (NCT00692770) | Bayer | 2008-08-15 |
| A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma (NCT00554372) | Jennerex Biotherapeutics | 2008-08-01 |
| Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer (NCT00699374) | Pfizer | 2008-07-01 |
| 11C-Acetate PET/CT Non-FDG-Avid Tumors (NCT00687778) | Tel-Aviv Sourasky Medical Center | 2008-05-01 |
| INSIGHT - Post Marketing Surveillance (NCT00792350) | Bayer | 2008-04-01 |
| Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE (NCT00936689) | Rita Golfieri | 2008-03-01 |
| Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) (NCT00703365) | Mahidol University | 2008-02-01 |
| Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors (NCT00610389) | Clinica Universidad de Navarra, Universidad de Navarra | 2008-02-01 |
| Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma (NCT00559455) | Sanofi | 2007-09-01 |
| SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma (NCT00503867) | Sirtex Medical | 2007-07-18 |
| Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) (NCT00508001) | Genzyme, a Sanofi Company | 2007-07-01 |
| Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients (NCT00470340) | Assistance Publique - Hôpitaux de Paris | 2007-06-01 |
| Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) (NCT00490685) | Istituto Clinico Humanitas | 2007-04-01 |
| Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients (NCT00471965) | Sanofi | 2007-03-01 |
| A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma (NCT00440934) | Pasche, Boris, M.D. | 2007-02-01 |
| Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma (NCT00662246) | National Cancer Center, Korea | 2007-01-01 |
| A Phase I Study of Pazopanib in Adult Patients With Liver Cancer (NCT00370513) | GlaxoSmithKline | 2006-12-06 |
| Use of N-Acetylcysteine During Liver Procurement (NCT01394497) | Azienda Ospedaliera di Padova | 2006-12-01 |